EUVIMEDEUVIMED entdecken
Crossref

Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program

Sydney Sheppard, Gerhard Hellemann, Jeffrey Lebensburger, Julie Kanter iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Sydney Sheppard und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 95% of children with sickle cell disease (SCD) survive into adulthood in the United States. However, early mortality remains a problem, especially in persons between the ages of 18 and 35. One possible explanation for the increased mortality rate in young adults is difficulties in engaging in care during the transition from a heavily contiguous pediatric healthcare model to a more self‐reliant adult healthcare model. The goal of this study was to identify potential facilitators and barriers to a successful transfer in care from the pediatric to adult SCD program before the formation of a formal transition program. This is a retrospective cohort study of transition outcomes for 472 individuals with SCD (all genotypes) treated at the University of Alabama at Birmingham (UAB) sickle cell clinic (aged 18–24). The primary outcome was whether the patient continued care in (any) adult SCD program (defined as being seen at least once in an adult hematology/SCD clinic). One hundred eighty‐eight (45%) transition age patients successfully transferred to adult care. Facilitators to successful transfer in care included being treated at the same hospital for both pediatric and adult programs, having the genotype HbSS, and/or receiving an SCD‐modifying therapy at the time of transition (hydroxyurea and/or red cell transfusion therapy). Of primary interest, many of the patients who failed to transition to an adult clinic were lost to follow‐up prior to 15 years of age. Importantly, these patients who had previously been labeled as “transition failures,” were lost to follow‐up long before the transition age. Early engagement is needed for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellYoung AdultHumansChildUnited StatesAdultAdolescentRetrospective StudiesHydroxyureaErythrocyte TransfusionHemoglobin, Sickle

Stichwörter der Autor:innen

hematologysickle celltransition

Substanzen

HydroxyureaHemoglobin, Sickle

Autor:innen und Institutionen

  • University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
  • Department of Biostatistics, University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA.
  • Division of Pediatric Hematology-Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
  • Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.

ORCID-Profile: Julie Kanter

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Sheppard, S., Hellemann, G., Lebensburger, J., & Kanter, J. (2023). Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30160

Vancouver

Sheppard S, Hellemann G, Lebensburger J, Kanter J. Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30160

BibTeX
@article{Sheppard2023,
  author = {Sheppard, Sydney and Hellemann, Gerhard and Lebensburger, Jeffrey and Kanter, Julie},
  title = {Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30160}
}
Kostenlos starten →